Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSEN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSEN1 Loop Domain / Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View PSEN1 Products |
| Gene Delivery | PSEN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Native 9-TM conformation preservation. |
View PSEN1 Products |
| Benchmark Ab | Anti-PSEN1 Recombinant Antibody Recombinant positive control for expression and localization. |
View PSEN1 Products |
| Validator | PSEN1 siRNA Set For target knockdown and specificity verification. |
View PSEN1 Products |
| Related Target A | Amyloid Precursor Protein (APP) Primary substrate cleaved by the PSEN1-containing gamma-secretase complex. |
View APP Products |
| Related Target B | NOTCH1 Critical off-target safety screening partner to avoid Notch-related toxicities. |
View NOTCH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native 9-TM Conformation | High-titer Lentivirus Premade Particles for stable cell line construction (HEK293/SH-SY5Y). |
| Notch-Sparing Selectivity Screening | Recombinant NOTCH1 extracellular domain and reporter assay materials for counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and biosimilars included. |
| False Positives in Knockdown | Chemically synthesized siRNA pools validated for sequence specificity and minimal off-target effects. |
Live PSEN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSEN1 therapeutics is intensifying, with major players shifting focus from traditional non-selective gamma-secretase inhibitors (GSIs) to Gamma-Secretase Modulators (GSMs). As first-generation therapies failed due to Notch pathway interference, the next wave of R&D is targeting conformation-specific modulation and mutation-specific (Familial AD) interventions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (GSMs) | Roche, Eisai, AstraZeneca | Alzheimer's Disease (AD) | Selectivity Assay (Need NOTCH1 vs APP cleavage differentiation) |
| Gene Therapy / ASO | Ionis Pharmaceuticals, Alnylam | Familial Alzheimer's Disease (FAD) | Target Knockdown Verification (Need high-specificity siRNA & qPCR controls) |
| Conformation-Specific mAbs | Academic Institutions, Biotech Startups | Early-Onset Neurodegeneration | Surface Expression & Binding Assays (Need Lentivirus-driven stable cell lines) |